Skip to Content
Merck
All Photos(1)

Documents

V-016

Supelco

Nicotinamide (Vitamin B3) solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Synonym(s):

Nicotinamide, Vitamin B3, Niacinamide, Nicotinic acid amide, Pyridine-3-carboxylic acid amide, Vitamin PP

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C6H6N2O
CAS Number:
Molecular Weight:
122.12
Beilstein:
383619
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

mp

128-131 °C (lit.)

application(s)

clinical testing
clinical testing

format

single component solution

storage temp.

−20°C

SMILES string

NC(=O)c1cccnc1

InChI

1S/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)

InChI key

DFPAKSUCGFBDDF-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Nicotinamide is also known as niacinamide or nicotinic acid amide. It is the water-soluble form of Vitamin B3 found in plant and animal foods and mostly used as a dietary supplement.

Application

This certified solution standard is suitable for a variety of testing applications including quality control testing by HPLC for pharmaceutical preparations or dietary supplements.
Nicotinamide may be used as an analytical reference standard for the determination of the analyte in energy drinks by planar chromatography-multiple detection with confirmation by electrospray ionization mass spectrometry and in pharmaceutical formulations, by UV-visible spectrophotometry and multivariate analysis.

Biochem/physiol Actions

Nicotinamide is an amide derivative of vitamin B3 and a PARP inhibitor

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.
Description
Pricing

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Simultaneous determination of riboflavin, pyridoxine, nicotinamide, caffeine and taurine in energy drinks by planar chromatography-multiple detection with confirmation by electrospray ionization mass spectrometry
Aranda M and Morlock G
Journal of Chromatography A, 1131(1-2), 253-260 (2006)
Simultaneous determination and classification of riboflavin, thiamine, nicotinamide and pyridoxine in pharmaceutical formulations, by UV-visible spectrophotometry and multivariate analysis
Lopez-de-Alba LP, et al.
Journal of the Brazilian Chemical Society, 17(4), 715-722 (2006)
Case of sorafenib-induced thyroid storm.
Sigurdis Haraldsdottir et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(16), e262-e264 (2013-04-24)
Takeshi Natori et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(5), 635-637 (2013-07-19)
Sorafenib is an oral multi-kinase inhibitor that targets tumor growth and angiogenesis signal transduction pathways. Two global phase III trials showed that sorafenib prolonged the survival of patients with advanced hepatocellular carcinoma (HCC). Based on the positive results of these
Noriaki Kitada et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(4), 479-482 (2013-07-16)
The current status of treatment with sorafenib, and factors affecting the duration of treatment in patients started on sorafenib for hepatocellular carcinoma from July 2009 until April 2011 in the Department of Gastroenterology at Kobe City Medical Center General Hospital

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service